Our group recently optimized tumor-localizing potential of TRAIL MSCs by the expression of an anti-GD2 chimeric antigen receptor (GD2 tCAR) (Golinelli et al., 2020; Golinelli et al., 2021). This evidence concerns the gene TNFSF10 and neoplasm.